Merck is set to pay $394 million to acquire Viralytics. The takeover will give Merck control of an oncolytic immunotherapy that Viralytics is testing in combination with Keytruda in early-phase trials.
Sydney-based Viralytics’ most advanced candidate is Cavatrak, a common cold RNA virus. Viralytics selected the nongenetically altered virus on the strength of its ability to target ICAM-1 and infect a variety of cancer cells. Once inside the cells, the virus starts wiping out the tumor through oncolytic and immunotherapeutic activity. That mechanism chimes with Merck’s strategy.
“Viralytics’s approach of engaging the innate immune system to target and kill cancer cells complements our immuno-oncology strategy,” Roy Baynes, head of global clinical development at Merck Research Laboratories, said in a statement. “We are eager to further build on Viralytics’s science as we continue our efforts to harness the immune system to improve long-term disease control and survival outcomes for people with cancer.”
Viralytics has some early clinical data to back up its approach to targeting tumors. Of particular relevance to Merck, a combination of Cavatrak and Keytruda triggered objective responses in 61% of the late-stage melanoma patients in a small, ongoing phase 1b trial. That suggests the combination is more effective than either drug in isolation.
The data contributed to Merck offering a 160% premium to acquire Viralytics. The Australian biotech’s largest shareholder plans to vote in favor of the takeover “in the absence of a superior proposal.” Merck expects to wrap up the buyout in the second quarter.
Viralytics is involved in three Cavatak-Keytruda combination trials. Merck was already collaborating with Viralytics on one of the trials, which is testing the cocktail in patients with bladder cancer and non-small cell lung cancer (NSCLC). The other two phase 1 trials are targeting patients with advanced melanoma and NSCLC.
The Keytruda combination is one big focus of Viralytics’ clinical trial strategy. That side of the R&D agenda should benefit from a closer relationship to Merck. The prospects for the other key pillar of Viralytics’ trial program, which is combining the oncolytic virus with Bristol-Myers Squibb’s Yervoy, is less certain.
By swooping on Viralytics, Merck has given itself a chance to differentiate its PD-1-based therapeutic regimens and offset the risk the proliferation of checkpoint inhibitors will devalue Keytruda. Similar thinking underpins other recent immuno-oncology deals, including Bristol-Myers’ partnership with Nektar Therapeutics.
By Nick Paul Taylor
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
